The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2019 | Challenges in using ALK inhibitors

Name: Challenges in using ALK inhibitors
Uploaded: 2019-04-16T13:00:54.000Z
Duration: 1 min 47 s
Description: Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the problems with molecularly guided sequencing of ALK (EML4-ALK fusion gene) inhibitors. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Girard explains the problems with current methods for screening mutations and the lack of a specific mechanism for identification.

Nicolas Girard • 16 Apr 2019

ELCC 2019

Lung Cancer Non-Small Cell Lung Cancer

Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the problems with molecularly guided sequencing of ALK (EML4-ALK fusion gene) inhibitors. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Girard explains the problems with current methods for screening mutations and the lack of a specific mechanism for identification.